DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Plenvu is a drug marketed by Salix and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and one patent family members in thirty-five countries.
The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.
Summary for PLENVU
Recent Clinical Trials for PLENVU
Identify potential brand extensions & 505(b)(2) entrants
|Istituto Clinico Humanitas||Phase 4|
|Quotient Clinical||Phase 1|
Recent Litigation for PLENVU
Identify potential future generic entrants
District Court Litigation
|BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC.||2019-04-01|
|Bausch Health Ireland Limited v. Lupin Ltd.|